The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Oynotkinova O.Sh.

Research Institute of Health Organization and Medical Management;
Central State Medical Academy of the Office of the President of the Russian Federation

Matskeplishvili S.T.

Lomonosov Moscow State University

Maslennikova O.M.

Central State Medical Academy of the Office of the President of the Russian Federation

Pavlov A.I.

National Medical Research Center for High Medical Technologies — Vishnevsky Central Military Clinical Hospital

Poberezhskaya A.G.

Sochi Central Clinical Hospital

Acetylsalicylic acid in primary and secondary prevention of atherosclerotic cardiovascular disease

Authors:

Oynotkinova O.Sh., Matskeplishvili S.T., Maslennikova O.M., Pavlov A.I., Poberezhskaya A.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5): 58‑64

DOI: 10.17116/jnevro202312305158

Read: 2660 times

Download PDF (RU)
Contact the author
Table of contents

ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

To cite this article:

Oynotkinova OSh, Matskeplishvili ST, Maslennikova OM, Pavlov AI, Poberezhskaya AG. Acetylsalicylic acid in primary and secondary prevention of atherosclerotic cardiovascular disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5):58‑64. (In Russ.)
https://doi.org/10.17116/jnevro202312305158

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Indi­cators of cognitive impairment of varying seve­rity in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):14-20
Repeated ischemic stro­kes due to infe­ctious arte­ritis of both inte­rnal caro­tid and basi­lar arte­ries as a complication of sphe­noiditis and otitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):31-37
Cases of successful thro­mbus extraction in ischemic stroke asso­ciated with the new coro­navirus infe­ction COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):38-46
On the issue of opti­mizing protein and energy supply for patients with acute cere­brovascular acci­dent. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):51-55
Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and reha­bilitation of patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):56-63
The randomized double-blind placebo-controlled study of effi­cacy and safety of mexi­dol in the complex therapy of ischemic stroke in the acute period. S.S. Korsakov Journal of Neurology and Psychiatry. 2006;(12-2):47-54
Asse­ssment of vole­mic status in acute period of ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2024;(5):64-71
Stage-by-stage treatment of a patient with severe combined trauma and heart rupture complicated by exte­nsive ischemic stroke. Piro­gov Russian Journal of Surgery. 2024;(10):121-129
Increasing the discharge epicrises info­rmative level of patients with transient ischemic atta­cks. Russian Journal of Preventive Medi­cine. 2024;(10):84-89
Adva­nces in thro­mbectomy in the acute ischemic stroke. Russian Journal of Preventive Medi­cine. 2024;(10):137-143

The article is devoted to an urgent problem — primary and secondary prevention of atherosclerotic cardiovascular diseases. Modern approaches to management tactics depending on age and the appointment of antiplatelet therapy with acetylsalicylic acid in low doses from 75 to 150 mg/day are presented. At the same time, the relatively high effectiveness of the use of ASA for primary prevention in men 40-69 years old without an increased risk of bleeding from the gastrointestinal tract is shown. Low doses of ASA provide little benefit in reducing the risk of CVD in people 40 years and older, when there is no history of CVD, but at the same time they are at increased risk of CVD.

Keywords:

primary
secondary prevention
atherosclerotic cardiovascular diseases
ischemic stroke
intestinal soluble acetylsalicylic acid
low doses

Authors:

Oynotkinova O.Sh.

Research Institute of Health Organization and Medical Management;
Central State Medical Academy of the Office of the President of the Russian Federation

Matskeplishvili S.T.

Lomonosov Moscow State University

Maslennikova O.M.

Central State Medical Academy of the Office of the President of the Russian Federation

Pavlov A.I.

National Medical Research Center for High Medical Technologies — Vishnevsky Central Military Clinical Hospital

Poberezhskaya A.G.

Sochi Central Clinical Hospital

Received:

18.04.2023

Accepted:

22.05.2023

List of references:

  1. Ogawa H, Nakayama M, Morimoto T, et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-2141. https://doi.org/10.1001/jama.2008.623
  2. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. https://doi.org/10.1136/bmj.a1840
  3. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-848.  https://doi.org/10.1001/jama.2010.221
  4. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304. https://doi.org/10.1056/NEJMoa050613
  5. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510-2520. https://doi.org/10.1001/jama.2014.15690
  6. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990—2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.  https://doi.org/10.1016/S0140-6736(15)60692-4
  7. Krishnamurthi RV, Moran AE, Feigin VL, et al. GBD 2013 Stroke Panel Experts Group. Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Adults Aged 20—64 Years in 1990—2013: Data from the Global Burden of Disease 2013 Study. Neuroepidemiology. 2015;45(3):190-202.  https://doi.org/10.1159/000441098
  8. Healthcare In Russia 2019. Stat. collection of Rosstat. M. 2019. (In Russ.).
  9. Martsevich SYu, Kutisenko NP, Zagrebelny AV, et al. Registry of acute cerebral circulatory disorders LIS-2: new data on long-term follow-up. Rational Pharmacotherapy in Cardiology. 2018;14(2):260-265. (In Russ.).
  10. Maksimova MYu. Current opportunities for secondary prevention of atherothrombotic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(8):97-105. (In Russ.). https://doi.org/10.17116/jnevro202112108197
  11. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis. 2003;16(suppl 10):14-19.  https://doi.org/10.1159/000069936
  12. Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in ath- erothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018;2(2):188-198.  https://doi.org/10.1002/rth2.12080
  13. Sato Y, Ishibashi-Ueda H, Iwakiri T. Thrombus components in cardioembolic and atherothrombotic strokes. Thromb Res. 2012;130(2):278-280.  https://doi.org/10.1016/j.thromres.2012.04.008
  14. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional out- come, survival, and recurrence. Stroke. 2000;31(5):1062-1068. https://doi.org/10.1161/01.str.31.5.1062
  15. Kennedy J, Hill MD, Ryckborst KJ, et al. FASTER Investigators. Fast assessment of stroke and transient isch- aemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6(11):961-969.  https://doi.org/10.1016/S1474-4422(07)70250-8
  16. Bhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189.  https://doi.org/10.1001/jama.295.2.180
  17. Tanashyan MM, Maksimova MYu, Zakharova MN, et al. Diagnostic technologies based on blood research. Neurology of the XXI century: diagnostic, therapeutic and research technologies. Chapter 7. M.: OOO «ATMO»; 2015. (In Russ.).
  18. Goff DC, Lloyd-Jones DM, Bennett A, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005
  19. Björklund L, Wallander MA, Johansson S, Lesén E. Aspirin in cardiology-benefits and risks. Int J Clin Pract. 2009;63(3):468-477.  https://doi.org/10.1111/j.1742-1241.2008.01908.x
  20. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.  https://doi.org/10.1136/bmj.324.7329.71
  21. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrom botic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):89-119.  https://doi.org/10.1378/chest.11-2293
  22. Nansseu JR, Noubiap JJ. Aspirin for primary prevention of cardiovascular disease. Thromb J. 2015;13:38.  https://doi.org/10.1186/s12959-015-0068-7
  23. Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force, f.S.E.R. U.S. Preventive Services Task Force Evidence Syntheses, Ed. Agency for Healthcare Research and Quality (US). 2015.
  24. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force. Ann Intern Med. 2016;54(8):45-51. 
  25. The US Preventive Services Task Force (USPSTF) members are listed at the end of this article. JAMA. 2022;327(16):1577-1584. https://doi.org/10.1001/jama.2022.4983
  26. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115(25):3156-3164. https://doi.org/10.1161/CIRCULATIONAHA.106.675587
  27. Guirguis-Blake JM, Evans CV, et al. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;327(16):1585-1597. https://doi.org/10.1001/jama.2022.3337
  28. Ganjehei L, Becker RC. Aspirin dosing in cardiovascular disease prevention and management: an update. J Thromb Thrombolysis. 2015;40(4):499-511.  https://doi.org/10.1007/s11239-015-1267-6
  29. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087-2116. https://doi.org/10.2165/11640880-000000000-00000
  30. Kitay AM, Ferstl FS, Link A, Geibel JP. Induction of Secretagogue Independent Gastric Acid Secretion via a Novel Aspirin-Activated Pathway. Front Physiol. 2019;10:1264. https://doi.org/10.3389/fphys.2019.01264
  31. Angiolillo DJ, Kastrati A, Simon DI. Clinical guide to the use of antithrombotic drugs in coronary artery disease. 2008, London: Informa Healthcare. xxviii, 276 p. 
  32. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5-6):255-258. 
  33. Elshafei MN, Imam Y, Alsaud AE, et al. The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. Eur J Clin Pharmacol. 2022;78:1801-1811. https://doi.org/10.1007/s00228-022-03391-2
  34. Gaglia MA Jr, Clavijo L. Cardiovascular pharmacology core reviews: aspirin. J Cardiovasc Pharmacol Ther. 2013;18(6):505-513.  https://doi.org/10.1177/1074248413503043
  35. Bliden KP, Patrick J, Pennell AT, et al. Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. Future Cardiol. 2016;12(1):45-58.  https://doi.org/10.2217/fca.15.60
  36. Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004;127(2):395-402.  https://doi.org/10.1053/j.gastro.2004.05.001
  37. Mohamed NE, Yahia I, Arwa EA, et al. The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. Eur J Clin Pharmacol. 2022;78(11):1801-1811. https://doi.org/10.1007/s00228-022-03391-2
  38. Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672-1691. https://doi.org/10.1093/eurheartj/ehy066
  39. Elshafei MN, Imam Y, Alsaud AE, et al. The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. Eur J Clin Pharmacol. 2022;78(11):1801-1811. https://doi.org/10.1007/s00228-022-03391-2
  • Falls in elderly and senile patients. Federation Health Ministry Clinical recommendations. 2020. (In Russ.). https://cr.rosminzdrav.ru/#!/recomend/1030
  • Chronic pain in elderly and senile patients. Russian Federation Health Ministry Clinical recommendations. 2020. (In Russ.). https://cr.rosminzdrav.ru/#!/recomend/1033
  • Clinical recommendations of the Ministry of Health of Russia «Gonarthrosis». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/667_1
  • Clinical recommendations of the Ministry of Health of Russia «Coxarthrosis». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/666_1
  • Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoart Cart. 2008;16 Suppl 3:S14-18.  https://doi.org/10.1016/j.joca.2008.06.008
  • Du Souich P, Garcia A,Verges J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;3(8A):1451-1463. https://doi.org/10.1111/j.1582-4934.2009.00826.x
  • de Abajo F, Gil M, Garcia Poza P, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23:1128-1138. https://doi.org/10.1002/pds.3617
  • King D, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. 2020;33(6):842-847.  https://doi.org/10.3122/jabfm.2020.06.200110
  • Bell G, Kantor E, Lampe J, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27(8):593-603.  https://doi.org/10.1007/s10654-012-9714-6
  • Morrison L. Reduction of ischemic coronary heart disease by chondroitin sulfate. Angiology. 1971;22(3):165-174.  https://doi.org/10.1177/000331977102200308
  • Morrison L, Enrick N. Coronary Heart Disease: Reduction of Death Rate By Chondroitin Sulfate. Angiology. 1973;24(5):269-287.  https://doi.org/10.1177/000331977302400503
  • Nakazawa K, Murata K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. Clinical Trial. Z Alternsforsch. 1979;34(2):153-159. 
  • Mazzucchelli R, Rodrı´guez-Martı´n S, Garcı´a-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS ONE. 2021;16(7):e0253932. https://doi.org/10.1371/journal.pone.0253932
  • Melgar-Lesmes P, Sánchez-Herrero A, Lozano-Juan F, et al. Chondroitin Sulphate Attenuates Atherosclerosis in ApoE Knockout Mice Involving Cellular Regulation of the Inflammatory Response. Thromb. Haemost. 2018;118(7):1329-1339. https://doi.org/10.1055/s-0038-1657753
  • Williams K, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-561.  https://doi.org/10.1161/01.atv.15.5.551
  • Adhikara I, Yagi K, Mayasari D, et al. Chondroitin Sulfate Nacetylgalactosaminyltransferase-2 Impacts Foam Cell Formation and Atherosclerosis by Altering Macrophage Glycosaminoglycan Chain. Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1076-1091. https://doi.org/10.1161/ATVBAHA.120.315789
  • Bell J, Rhind S, Di Battista A, et al. Biomarkers of glycocalyx injury are associated with delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage: a case series supporting a new hypothesis. Neurocrit Care. 2016;26(3):339-347.  https://doi.org/10.1007/s12028-016-0357-4
  • Nuytemansa K, Ortelb T, Gomeza L, et al. Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thromb Res. 2018;161:43-51.  https://doi.org/10.1016/j.thromres.2017.11.016
  • Ye J, Esmon C, Johnson A. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem. 1993;268(4):2373-2379.
  • McGee M, Wagner W. Chondroitin Sulfate Anticoagulant Activity Is Linked to Water Transfer Relevance to Proteoglycan Structure in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(10):1921-1927. https://doi.org/10.1161/01.ATV.0000090673.96120.67
  • Moroudas A, Weinberg P, Parker K, Winlove C. The distribution and diffusion of small ions in chondroitin sulfate, hyaluronate and some proteoglycans solutions. Biophys Chem. 1988;32(2-3):257-270.  https://doi.org/10.1016/0301-4622(88)87012-1

    • Close metadata

    Contact the author
    Email
    Message
    The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

    Email Confirmation

    An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

    Email Confirmation

    Contact us
    If you have any questions, complaints or suggestions, please use this feedback form.
    Email
    Message
    The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
    Submit Application

    You can become an author of one of our magazines, send a request and we will consider it in during the day.

    Name
    Phone
    E-mail
    Message
    Login
    Registration
    E-mail
    Password
    Forgot Password?

    Log in to the site using your account in one of the services

    Password recovery
    E-mail
    Login
    Register

    We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.